In the tumor microenvironment, combinations of multi-points of blockade (PD-L1, CTLA-4, TIM3), combining radiation therapy with those ICIs, and immune modulation that uses sunitinib or L-arginine will again attempt to redefine the tumor microenvironment and redefine the immune response [99,100] Figure 1. The gene discussed is CTLA4; the disease is neoplasm.